| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705376 | Ophthalmology | 2017 | 9 Pages |
Abstract
In the United States, anti-VEGF injection was the most frequently utilized treatment for mCNV. Those treated were observed to gain vision. However, one quarter of patients received no treatment and lost vision. Further studies are needed to understand the sociodemographic and health-systems barriers surrounding the delivery of anti-VEGF injections to patients with mCNV.
Keywords
NOSIntelligent Research in SightlogMARICD-9-CMU.S.PDTAORCPTstandard deviationUnited StatesVisual acuityNot otherwise specifiedPhotodynamic therapyinternational classification of diseases, ninth revision, clinical modificationIrisconfidence intervalVascular Endothelial Growth Factor (VEGF)adjusted odds ratio
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jeffrey MD, PhD, Lawrence MD, PhD, Susan MHS, PhD, David W. MD, William L. MD, Flora MD, Ronald A. PhD,